IPK Superfamily

Inositiol Polyphosphate Kinase (IPK) Superfamily

Inositiol Polyphosphate Kinase (IPK) Superfamily is a family of enzymes that have a similar 3-dimensional structure. All members of the family catalyze the transfer of phosphate groups from ATP to various inositol phosphates. Members of the family include inositol-polyphosphate multikinases (IPMK), inositol-hexakisphosphate kinases, inositol-trisphosphate 3-kinases (PI3K) and inositol-pentakisphosphate 2-kinase (IP5P2K). Members of the IPK superfamily play important roles in various signaling pathways by altering the phosphorylation state of the second messenger inositol phosphates. Some members of the IPK superfamily are involved in regulating inositol phosphate metabolism related to vesicle transport, ensuring the accurate progress of intracellular substance transport. Abnormal functions of IPK superfamily members are closely related to the occurrence and development of various diseases, such as cancer, neurological diseases, and metabolic diseases^[1]^[2]^[3].

References:

[1]. Xiong T, et al. Origin, evolution, and diversification of inositol 1,4,5-trisphosphate 3-kinases in plants and animals. BMC Genomics. 2024 Apr 8;25(1):350.

[2]. Malabanan MM, et al. Inositol polyphosphate multikinase (IPMK) in transcriptional regulation and nuclear inositide metabolism. Biochem Soc Trans. 2016 Feb;44(1):279-85. [Content Brief]

[3]. Kim E, et al. IPMK: A versatile regulator of nuclear signaling events. Adv Biol Regul. 2016 May;61:25-32. [Content Brief]

IPK Superfamily Related Products (9):

By Effects:	Inhibitors (7) Agonists (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-150607

UNC7467	Inhibitor	98.07%
UNC7467 is a potent IP6K inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research.

HY-110079

TNP	Inhibitor	99.29%
TNP is a cell-permeable inhibitor of IP6K1 and IP3K, with IC₅₀ values of 0.55 µM and 10.2 µM for IP3K, respectively. TNP binds to the ATP-binding sites of both enzymes.

HY-153530

LI-2242	Inhibitor	98.95%
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC₅₀ values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders.

HY-P4195A

[K15,R16,L27]VIP(1-7)/GRF(8-27) acetate	Agonist	98.01%
[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is the acetate of [K15,R16,L27]VIP(1-7)/GRF(8-27) (HY-P4195). [K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate), a VIP₁ selective agonist, exhibits IC₅₀ values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP₁, rat VIP₁, rat VIP₂ receptors, respectively. VIP: VASOACTIVE Intestinal Polypeptide

HY-P4195

[K15,R16,L27]VIP(1-7)/GRF(8-27)	Agonist
[K15,R16,L27]VIP(1-7)/GRF(8-27), a VIP₁ selective agonist, exhibits IC₅₀ values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP₁, rat VIP₁, rat VIP₂ receptors, respectively. VIP: VASOACTIVE Intestinal Polypeptide

HY-122706A

IP6K2-IN-2	Inhibitor	98.85%
IP6K2-IN-2 (Compound 6) is an IP6K2 inhibitor, with IC₅₀ values of 0.58 μM (IP6K2), 0.86 μM (IP6K1) and 3.08 μM (IP6K3). IP6K2-IN-2 can be used in research of obesity.

HY-162821

LI-3948	Inhibitor
IP6K-IN-2 (compound 29c) is an orally bioavailable and blood-brain barrier permeable IP6K inhibitor (IC₅₀: 15.8 nM) that can be used in the study of central nervous system diseases.

HY-162016

IP6K-IN-1	Inhibitor
IP6K-IN-1 (compound 24) is a potent and selective inhibitor of IP6K with an IC₅₀ of 0.896 μM. IP6K-IN-1 can used in study metabolic disease.

HY-161032

IP6K2-IN-1	Inhibitor
IP6K2-IN-1 (Compd 20s) is a selective IP6K2 inhibitor, with an ICIC₅₀ value of 0.55 μM.

Name
Email *

	Sorry, but the email address you supplied was invalid.